Impel NeuroPharma Inc. has closed $36 million in Series C funding from Bay Area investment companies venBIO, 5AM Ventures and Vivo Capital.
Seattle-based Impel NeuroPharma, which develops device-drug combinations that deliver medicine through a patient’s upper nasal cavity, will use the funds to push its migraine treatment to the market.
“The nasal cavity is a vastly underutilized entry point for therapeutics into the circulation,” said Impel NeuroPharma CEO John Hoekman in a statement. “Our…
Impel NeuroPharma Inc. has closed $36 million in Series C funding from Bay Area investment companies venBIO, 5AM Ventures and Vivo Capital.
Seattle-based Impel NeuroPharma, which develops device-drug combinations that deliver medicine through a patient’s upper nasal cavity, will use the funds to push its migraine treatment to the market.
“The nasal cavity is a vastly underutilized entry point for therapeutics into the circulation,” said Impel NeuroPharma CEO John Hoekman in a statement. “Our…